HER2+ Breast Cancer

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.

Neelam Desai, MD, highlights the phase 3 PATINA study evaluating a palbociclib-based regimen in HR-positive/HER2-positive metastatic breast cancer.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Panelists discuss how the treatment landscape for early HER2-positive metastatic breast cancer has evolved, with taxane-pertuzumab-trastuzumab as first-line standard of care and T-DXd supplanting T-DM1 as the preferred second-line treatment.

Panelists discuss how different gonadotropin-releasing hormone (GnRH) agonists like leuprolide and goserelin are equally efficacious for ovarian function suppression but differ in administration methods, needle size, and patient comfort.

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

The next-generation ADC ARX788 is under investigation in the phase 2 ACE-Breast-03 trial of patients with T-DXd–pretreated HER2-positive breast cancer.

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Neelam Desai, MD, discusses the role of a palbociclib-containing regimen in HR-positive, HER2-positive metastatic breast cancer.

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Japan’s Ministry of Health has received a supplemental new drug application for T-DXd for HER2-positive advanced or recurrent solid tumors.

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.